Trinity Biotech (TRIB) Revenue (2009 - 2024)

Trinity Biotech (TRIB) has reported Revenue for 16 consecutive years, with $15.9 million the latest figure, recorded in Q4 2024.

• Quarterly Revenue rose 18.09% year-over-year to $15.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $61.6 million (up 8.31% YoY) and the FY2025 annual result came in at $43.8 million, down 28.87% from the prior year.
• Revenue advanced to $15.9 million in Q4 2024 per TRIB's latest filing, from $15.2 million in the prior quarter.
• Over the last five years, Revenue for TRIB reached as high as $32.8 million in Q4 2020 and fell as low as $13.4 million in Q4 2023.
• A 5-year average of $18.8 million and a median of $15.8 million in 2022 frame the typical range for Revenue.
• The largest YoY upside for Revenue was 61.28% in 2021 against a maximum downside of 40.41% in 2021.
• Year by year, Revenue stood at $32.8 million in 2020, then slumped by 40.41% to $19.5 million in 2021, then fell by 19.46% to $15.7 million in 2022, then declined by 14.61% to $13.4 million in 2023, then rose by 18.09% to $15.9 million in 2024.
• According to Business Quant data, Revenue over the past three periods registered $15.9 million, $15.2 million, and $15.8 million for Q4 2024, Q3 2024, and Q2 2024 respectively.